BJO

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH REGISTER


[Advanced]
The most recent version of this article was published on 1 October 2007

Br J Ophthalmol. Published Online First: 7 June 2007. doi:10.1136/bjo.2007.124081
Copyright © 2007 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
bjo.2007.124081v1
91/10/1341    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Micheal J Gallagher
C Stephen Foster
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gallagher, M. J
Right arrow Articles by Foster, C S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gallagher, M. J
Right arrow Articles by Foster, C S.

Clinical science - Extended reports

Biologic Response Modifier Therapy for Refractory Childhood Uveitis

Micheal J Gallagher 1, Karina Quinones 1, Rene A Cervantes-Castañeda 1, Taygan Yilmaz 1 and C Stephen Foster 1*

1 MERSI, United States

* To whom correspondence should be addressed. E-mail: sfoster{at}mersi.us.

Accepted 21 May 2007


*  Abstract

Purpose: To evaluate the use of biologic response modifiers (BRM's) in the treatment of refractory childhood uveitis.

Design: Retrospective non comparative case series of pediatric patients with uveitis treated with BRM's.

Participants: 23 pediatric patients.

Methods: All children (18 years or younger) who received a BRM were assessed for visual changes, time to control inflammation, and any associated adverse side effects. Thirteen patients were treated with infliximab, five with adalimumab, and five with daclizumab. All patients had bilateral eye involvement. Diagnoses of the participants included juvenile idiopathic arthritis, keratouveitis, sarcoid panuveitis, Adamantiades- Behcets disease, and idiopathic panuveitis.

Main outcome Measures: Inflammation and visual acuity.

Results: In the infliximab group 16 of 26 (62%) eyes, and 10 of 13 (77%) patients demonstrated an improvement in visual acuity. Twenty of 26 (77%) patients demonstrated an improvement in the degree of inflammation. In the adalimumab group 4 of 10 (40%) eyes demonstrated an improvement in visual acuity with 5 of 10 (50%) patients demonstrating an improvement in inflammation. Four of 10 (40%) eyes in the daclizumab group demonstrated an improvement in vision with 8 of 10 (80%) patients demonstrating an improvement in inflammation.

Conclusions: BRM's appear to be safe to use in children, and represent a useful therapeutic adjunctive drug group for treating recalcitrant childhood uveitides.

Keywords: Biologic Response modifier Therapy, TNF-alpha Inhibitors, Uveitis, childhood




This article has been cited by other articles:


Home page
 IOVSHome page
R. T. Ramadan, A. L. Moyer, and M. C. Callegan
A Role for Tumor Necrosis Factor-{alpha} in Experimental Bacillus cereus Endophthalmitis Pathogenesis
Invest. Ophthalmol. Vis. Sci., October 1, 2008; 49(10): 4482 - 4489.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
G. Simonini, M. E. Zannin, R. Caputo, F. Falcini, M. de Martino, F. Zulian, and R. Cimaz
Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis
Rheumatology, October 1, 2008; 47(10): 1510 - 1514.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2007 by the BMJ Publishing Group Ltd.